Evaluation of properties microcrystalline chitosan as a drug carrier. Part 1. In vitro release of diclofenac from mictocrystalline chitosan hydrogel

The influence of microcrystalline chitosan hydrogel, alone (MCCh) as well as in combination with methylcellulose (MC) or Carbopol (CP), on the release of diclofenac free acid (DA) and its salt (DS) was studied in vitro. Commercial Olfen gel (Mepha Ltd., Switzerland) was applied as a reference preparation. The influence of hydrophilizing agents (1,2-propylene glycol and glycerol) and methycellulose hydrogel on the rheological properties of the vehicle and on the release of drug from modified MCCh hydrogel was studied. The quantity of the released substance was determined by UV-spectroscopy. The results confirmed that release was dependent on the chemical character of the drug and on the type of vehicle. The process of diclofenac release from MCCh hydrogels as well as from Carbopol hydrogels runs in two phases. The first phase is characterised by rapid release whereas in the second phase the release is much slower. The most suitable basis for diclofenac is microcrystalline chitosan hydrogel with addition glycerol, 1,2-propylene glycol, and methylcellulose hydrogel.     

In vitro evaluation of microcrystalline chitosan (MCCh) as gel-forming excipient in matrix granules.

Although much research has been carried out into the effects of chitosan and its chemical properties on drug release, less attention has been paid to the effects of its physical properties. The aim of this study was to characterize microcrystalline chitosan (MCCh) as a gel-forming excipient. Matrix granules containing chitosans of differing physicochemical properties (crystallinity, molecular weight, degree of deacetylation) and ibuprofen or paracetamol as model drugs were prepared. Gel formation by the chitosans in the granules and subsequent effects on drug release were studied at pH 1.2 and pH 5.8. The chitosan granules acted as slow-release formulations in the case of ibuprofen (a class-II drug in the Biopharmaceutics Classification System) but with paracetamol (class-I) no controlled-release formulation could be developed. Microcrystalline grades of chitosan had the most marked retardant effects on drug release, with the efficacy of gel formation by MCCh explaining the results. The kinetic constant for ibuprofen release (at pH 5.8) ranged from 22%.h(-1) (MCCh) to 31%.h(-1) (unmodified chitosan). The release rate was easily controlled by varying the amount or molecular weight of MCCh, and to a lesser extent by the degree of deacetylation. The effects were most pronounced when pH was markedly acidic, suggesting that MCCh granules might be particularly useful in preparing stomach-specific slow-release dosage forms.     

In vivo evaluation of matrix granules containing microcrystalline chitosan as a gel-forming excipient

Interest in drug delivery to the gastrointestinal tract by means of chitosan has been increasing. In the study reported, the biopharmaceutical properties of granules containing microcrystalline chitosan (MCCh; molecular weight 150 kDa, degree of deacetylation 75%) were evaluated via bioavailability tests in human volunteers. Ibuprofen and furosemide were used as model drugs. With ibuprofen, granules containing 40% of MCCh behaved as a slow-release formulation (t(max) 2.9 h). With furosemide, the most marked difference between a conventional dosage form and granules containing 40% MCCh was a marked lag time (0.5 h) before absorption from the latter. This difference was reflected in t(max) values for furosemide. Despite the lag time, AUC values for furosemide were high, indicating that the granules containing MCCh had remained in the stomach and that drug release had taken place in the stomach rather than in the intestine. The results of the bioavailability studies indicate that MCCh matrix granules allow a simple preparation of slow-release and perhaps stomach-specific dosage forms. Use of model drugs differing in relation to sites of absorption in the gastrointestinal tract aided identification of sites of absorption of drugs from the granules. Further studies, including gamma-scintigraphic evaluations, will be performed on how the granules behave in the stomach.     

Release kinetics of basic fibroblast growth factor (bFGF) from certain biopolymers in the presence of ketoprofen

The aim of the present study was the evaluation of basic fibroblast growth factor (bFGF, FGF-2) release in vitro from four types of polymer bases (carriers), fibrin, microcrystalline chitosan (MCCh), fibrin and MCCh, as well as MCCh and methylcellulose (MC) in the presence or absence of ketoprofen (KTA). Amount of released basic fibroblast growth factor was measured immunoenzymatically using Elisa (R&D System). Ketoprofen concentration was determined spectrophoto-metrically at 255 nm, using an appropriate absorbance factor, alpha 1 cm (1%) = 662. The most significant influence of ketoprofen on bFGF release was seen in the case of microcrystalline chitosan carrier elution. Parameters of the equation which describe the amount of bFGF released from chitosan carrier with and without KTA are y = 6.842 +/- 1.637 In(t) + 14.935 +/- 2.378, determination coefficient, R2 = 0.9332 and y = 4.070 +/- 0.622 In(t) + 10.589 +/- 1.011, determination coefficient, R2 = 0.9606. The time after which 20% of bFGF was released (t 20%) in the presence of ketoprofen was 2.1 h whereas it was significantly longer without ketoprofen (10.1 h). The amount of bFGF released from fibrin carrier was lower in the presence of ketoprofen. The time taken for 20% of bFGF to be released (t 20%) was very long (41.7h) in the presence of KTA and 16.3 h. without KTA. The other carriers (fibrin + MCCh and MCCh + MC) in the presence of ketoprofen appear to have an insignificant influence on the kinetics of basic fibroblast growth factor release. For the chitosan carrier (p = 0.05, and also p = 0.01, when t(theoret) = 2.921), there is a statistically significant difference between the coefficients (a1 and a2) of the regression equation describing the process of basic fibroblast growth factor release from the base with and without ketoprofen. It was also found that the amount of ketoprofen released varied considerably according to the carrier. All results clearly indicate that the type of carrier not only has an impact on the amount of bFGF released, but also on the kinetics of ketoprofen release.     

Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach.

In several reports of in vitro studies it has been suggested that the mucoadhesive chitosans could be of value in preparing gastro-retentive formulations. The aim of this study was to obtain direct in vivo evidence of whether microcrystalline chitosan (MCCh) formulations acted as gastro-retentive systems in humans. Neutron-activation-based gamma scintigraphy was used to study gastric residence times of MCCh granules in healthy male volunteers. Possible effects of neutron irradiation on the properties of the MCCh granules were studied in advance, in vitro. In vivo gamma scintigraphic evaluations were carried out with the subjects in a fasted state, using granules containing 95% (F1) or 40% (F2) of MCCh of molecular weight 150 kDa. Reference formulation (F3) was lactose granules. The reference granules passed rapidly from the stomach (mean t50% 0.5+/-0.3 h (n=5)). MCCh in granules prolonged gastric residence times of the formulations in only a few cases (in one volunteer in the F1 group (n=4) and in two volunteers in the F2 group (n=5)). Maximum individual t50% values were 2.1 h (F1) and 2.3 h (F2). It was concluded that the in vivo mucoadhesion of MCCh formulations is erratic, and that the formulations studied are not reliable gastro-retentive drug delivery systems.     

Evaluation of microcrystalline chitosans for gastro-retentive drug delivery

In vivo absorption studies were carried out in human volunteers to evaluate whether microcrystalline chitosan (MCCh) granules would be gastro-retentive. Furosemide, which is site-specifically absorbed from the upper gastrointestinal tract, was used as model drug. The rate of release of furosemide in vitro could be prolonged by increasing the molecular weight (M_w) or amount of MCCh (150 to 240 kDa; 80 to 95%) in the granules, and also by addition of acidic excipients to the formulations. No marked changes in the in vivo absorption rate (t_max) were noted, but the amounts of furosemide absorbed (AUC_0–∞ and C_max) decreased as the in vitro release rate decreased, although this was not statistically significant in the case of AUC. The highest AUC_0–∞ (3050 μg l⁻¹ h) for furosemide (40 mg) was achieved with granules containing 80% MCCh of 150 kDa M_w. With MCCh of 240 kDa M_w AUC_0–∞ was 1890 μg l⁻¹ h. This kind of pharmacokinetic profile of furosemide suggests that the gastric retention time of the granules is too short in relation to the release rate, and a large amount of the drug passes its “absorption window” before being released. The in vivo study produced no evidence that the chitosan formulations studied can be used as mucoadhesive gastro-retentive drug delivery systems. The results of in vitro mucoadhesion studies did not predict the results of in vivo studies.     

Decrease in serum LDL cholesterol with microcrystalline chitosan.

Peroral microcrystalline chitosan (MCCh; 3 capsules, each 400 mg b.i.d.) or placebo was given for 8 weeks in a double-blind manner to 51 healthy obese women just before routine hospital and home meals. Weight records, serum lipids (total, LDL and HDL cholesterol, triglycerides) and safety laboratory parameters were monitored before the trial and at 4, 6 and 8 weeks of treatment. In a subgroup of subjects with a body mass index > or = 30 who had not changed their eating habits, serum LDL cholesterol decreased 0.57 +/- 0.72 mmol/l (n = ll) at 4 weeks in the MCCh group and 0.10 +/- 0.60 mmol/l (n = 14) in the placebo group (p < 0.05). At 8 weeks, LDL cholesterol reduction was 0.48 +/- 0.91 mmol/l in the MCCh group and 0.26 +/- 0.57 mmol/l in the placebo group (p > 0.1). In all subjects, the reduction in LDL cholesterol at 4 weeks was 0.48 +/- 0.72 mmol/l (n = 24) in MCCh subjects and 0.18 +/- 0.58 mmol/l (n = 27) in placebo subjects (p = 0.057), and 0.52 +/- 0.69 mmol/l and 0.31 +/- 0.63 mmol/l, respectively, at 8 weeks (p > 0.1). MCCh did not significantly alter serum total and HDL cholesterol (p > 0.1), but slightly increased serum triglycerides compared to placebo (p = 0.015-0.06). No reductions in weight were observed in any treatment group. Chitosan was well tolerated and no serious adverse events or changes in safety laboratory parameters were noted including serum fat-soluble vitamins A and E, and serum Fe++ and transferrin.     

Effect of microcrystalline chitosan on the solubility of ibuprofen

It was found that MCCh may be used for the enhancement of the solubility and dissolution rates of drugs. The solubility of IBA in water increased significantly (about 10-fold) when MCCh was added. Differential scanning calorimetry (DSC), powder X-ray diffractometry, and IR spectroscopy were used to confirm that salt links between the drug and MCCh occurred.     

A thermo- and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate

The quaternized chitosan was synthesized by the reaction of chitosan and glycidyltrimethylammonium chloride (GTMAC) and named as N-[(2-hydroxy-3-trimethylammonium) propyl] chitosan chloride (HTCC). A novel hydrogel system composed of HTCC/glycerophosphate (HTCC/GP) with thermo- and pH-sensitivity was synthesized and used as an intelligent drug carrier. The formulation was solution below or at room temperature, which allowed it injectable and to incorporate living cells, proteins, enzymes or other therapeutic drugs easily. Once the surrounding temperature was up to 37 degrees C, the system was transformed to a non-flowing hydrogel, and the formed hydrogel can release the trapped drug as a function of pH values. The swelling behavior of the system and the release profiles of doxorubicin hydrochloride (DX) as a model drug at different pH values were investigated. At acidic condition the hydrogel dissolved and released drug quickly, while it absorbed water and released drug slowly at neutral or basic conditions. Hydrogel composed of chitosan hydrochloride and glycerophosphate (CS/GP) was also prepared to compare with HTCC/GP hydrogel. The HTCC/GP hydrogel in this study was transparent which made it suitable for some specific uses such as ocular drug formulation.     

SCS药物缓释凝胶的制备及其体外释药研究

以壳聚糖硫酸酯作为骨架材料,盐酸诺氟沙星为模型药物。研究壳聚糖硫酸酯凝胶在药物缓释中的应用。探讨盐酸诺氟沙星缓释凝胶的体外释药规律。初步阐明其释药机理。考察支联度、投药量、温度、不同释放介质对释药的影响。结果表明盐酸诺氟沙星缓释凝胶有一定的缓释特性,且具有温度／pH敏感性。     

A multiple emulsion method to entrap a lipophilic compound into chitosan microspheres

A new method for preparation of chitosan microspheres loaded with an hydrophobic drug, ketoprofen, was developed. It is an emulsification/solvent evaporation process carried out in mild conditions and particularly useful for microencapsulation of thermally sensitive drugs. This method can be additionally combined to physical and chemical cross-linking in order to modulate drug release. Physical cross-linking was carried out by dry heating chitosan microspheres at fixed temperatures and for different times. Glutaraldehyde at different concentrations was used as the chemical cross-linking agent on microspheres constituted by different theoretical ketoprofen/chitosan ratio (1:2, 1:4, 1:6 w/w). Chitosan microspheres were morphologically characterized for shape, surface characteristics and size distribution; chitosan/ketoprofen interactions inside microspheres were investigated by differential scanning calorimetry and powder X-ray difractometry. Ketoprofen contents inside the microspheres and in vitro drug release profiles were also determined.     

Novel pH-sensitive citrate cross-linked chitosan film for drug controlled release

Turbidimetric titration revealed that there were electrostatic attractive interactions between citrate and chitosan in the pH region of 4.3-7.6, depending on their degree of ionization. Citrate cross-linked chitosan film was prepared simply by dipping chitosan film into sodium citrate solution. The swelling ratio of citrate/chitosan film was sensitive to pH, ionic strength etc. Under acidic conditions, citrate/chitosan film swelled and even dissociated in the pH less than 3.5, and the model drugs (brilliant blue and riboflavin) incorporated in the film were released quickly (usually within 2 h released completely in simulated gastric fluid at 37 degrees C) while under neutral conditions the swelling ratio of citrate/chitosan film was less significant and the release rate of brilliant blue and riboflavin was low (less than 40% released in simulated intestinal fluid in 24 h). Sodium chloride weakened the electrostatic interaction between citrate and chitosan, and therefore facilitated the film swelling and accelerated drug release. The parameters of film preparation such as citrate concentration, solution pH etc. influencing the film swelling and drug release profiles were examined. The lower concentration and the higher pH of citrate solution resulted in a larger swelling ratio and quicker riboflavin release. To improve the drug controlled release properties of citrate/chitosan film, heparin, pectin and alginate were further coated on the film surface. Among them only the coating of alginate prolonged riboflavin release noticeably (for 80% of drug released the time was extended from 1.5 to 3.5 h with 0.5% w/v alginate used). The results indicated that the citrate/chitosan film was useful in drug delivery such as for the site-specific drug controlled release in stomach.     

用于关节腔注射的马钱子碱壳聚糖温敏凝胶的研究

利用壳聚糖-甘油-饱和硼砂溶液为主要材料构建一种用于关节腔注射、具有缓释作用的壳聚糖反相温敏水凝胶系统,并对其理化性质和生物相容性进行初步研究。以凝胶的形成和胶凝时间为指标,考察壳聚糖浓度、壳聚糖与甘油的比例、pH值等因素对水凝胶理化性质的影响,并对其体外释放行为、流变学、生物相容性等特性进行表征。温敏凝胶在常温下为溶胶态,当处于37℃时转变为凝胶态,并具有一定的缓释效果,生物相容性较高。     

Synthesis and characterization of cross-linked chitosan microspheres for drug delivery applications

The present study deals with the synthesis and characterization of cross-linked chitosan microspheres containing an hydrophilic drug, hydroquinone. The microspheres were prepared by the suspension cross-linking method using glutaraldehyde as the cross-linking agent of the polymer matrix. Perfectly spherical cross-linked hydrogel microspheres loaded with hydroquinone were obtained in the size range of 20–100 μm. The effect of the degree of polymer cross-linking, chitosan molecular weight, chitosan concentration and amount of the encapsulated drug on the hydroquinone release kinetics was extensively investigated. It was found that slower drug release rates were obtained from microspheres prepared by using a higher initial concentration of chitosan, a higher molecular weight of chitosan or/and a lower drug concentration. Most importantly, it was shown that the release rate of hydroquinone was mainly controlled by the polymer cross-linking density and, thus, by the degree of swelling of the hydrogel matrix.     

Release characteristics of chitosan treated alginate beads: I. Sustained release of a macromolecular drug from chitosan treated alginate beads

Alginate and chitosan treated alginate beads were prepared and compared as an oral controlled release system for macromolecular drugs. Dextran (M.W. 70,000) was used as a model substance. The beads were prepared by the ionotropic gelation method and the effect of various factors (alginate, chitosan, drug and calcium chloride concentrations, the volume of external and internal phases and drying methods) on bead properties were investigated. The addition of chitosan increased the drug loading capacity of the beads, and larger beads were obtained in the presence of chitosan. On the other hand, addition of chitosan in the gel structure reduced the drug release from beads. The erosion of the beads was suppressed by chitosan treatment. The drying method was important to the properties of the chitosan-alginate beads. It is proposed that chitosan treated alginate beads may be used as a potential controlled release system of such macromolecules.     

Synthesis and characterization of cross-linked chitosan microspheres for drug delivery applications

The present study deals with the synthesis and characterization of cross-linked chitosan microspheres containing an hydrophilic drug, hydroquinone. The microspheres were prepared by the suspension cross-linking method using glutaraldehyde as the cross-linking agent of the polymer matrix. Perfectly spherical cross-linked hydrogel microspheres loaded with hydroquinone were obtained in the size range of 20-100 microm. The effect of the degree of polymer cross-linking, chitosan molecular weight, chitosan concentration and amount of the encapsulated drug on the hydroquinone release kinetics was extensively investigated. It was found that slower drug release rates were obtained from microspheres prepared by using a higher initial concentration of chitosan, a higher molecular weight of chitosan or/and a lower drug concentration. Most importantly, it was shown that the release rate of hydroquinone was mainly controlled by the polymer cross-linking density and, thus, by the degree of swelling of the hydrogel matrix.     

Multiunit controlled-release diclofenac sodium capsules using complex of chitosan with sodium alginate or pectin

This study explored the application of chitosan-alginate (CA) and chitosan-pectin (CP) complex films as drug release regulator for the preparation of multiunit controlled-release diclofenac sodium capsules. Pellets containing drug and microcrystalline cellulose, in a ratio of 3:5, were prepared in a fluidized rotary granulator. The pellets were coated with CA, CP, sodium alginate, pectin, and chitosan solutions. The pellets, equivalent to 75 mg drug, were filled into capsules. After 2 h of dissolution test in acidic medium, the amount of the drug released from any preparation was negligible. The pellets were further subject to pH 6.8 phosphate buffer More than 80% drug release at 12 h was observed with the uncoated pellets and those coated with sodium alginate, pectin or chitosan. Both 1% CA and 3% CP coated pellets exhibited drug release profiles similar to that of Voltaren SR75. It was found that approximately 60% and 85% of the drug were released at 12 and 24 h, respectively. Both Differential thermal analysis (DTA) and Fourier transform infrared spectroscopy (FTIR) analyses revealed complex formation between chitosan and these anionic polymers. It could be concluded that CA and CP complex film could be easily applied to diclofenac sodium pellets to control the release of the drug.     

壳聚糖季铵盐温敏凝胶的制备及性能考察

目的 研究壳聚糖季铵盐温敏凝胶及性质.方法 采用试管倾斜法测定胶凝时间,考察壳聚糖季铵盐的浓度、体积比、温度等对胶凝时间的影响,采用吸光度经时变化法测定相变动力学,并用透析法测定载药凝胶的体外释放.结果 56％ GPS/2％ HTCC体积配比1:5、温度37℃时,胶凝时间为3.53min,钙黄绿素载药凝胶具有良好的缓释...     

Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum

The aim of this study was to investigate the influence of pH, buffer species and ionic strength on the release mechanism of chlorpheniramine maleate (CPM) from matrix tablets containing chitosan and xanthan gum prepared by a hot-melt extrusion process. Drug release from hot-melt extruded (HME) tablets containing either chitosan or xanthan gum was pH and buffer species dependent and the release mechanisms were controlled by the solubility and ionic properties of the polymers. All directly compressed (DC) tablets prepared in this study also exhibited pH and buffer species dependent release. In contrast, the HME tablets containing both chitosan and xanthan gum exhibited pH and buffer species independent sustained release. When placed in 0.1N HCl, the HME tablets formed a hydrogel that functioned to retard drug release in subsequent pH 6.8 and 7.4 phosphate buffers even when media contained high ionic strength, whereas tablets without chitosan did not form a hydrogel to retard drug release in 0.1N HCl. The HME tablets containing both chitosan and xanthan gum showed no significant change in drug release rate when stored at 40 °C for 1 month, 40 °C and 75% relative humidity (40 °C/75% RH) for 1 month, and 60 °C for 15 days.     

The delivery of platinum drugs from thermosensitive hydrogels containing different ratios of chitosan

New thermosensitive hydrogels of poly(N-isopropylacrylamide) (PNIPAAm) with chitosan (CPN) were prepared and evaluated for use in the delivery of the platinum drugs, cisplatin and carboplatin. The effects of polymers containing different ratios of chitosan on the physicochemical and drug release characteristics were examined. The sol-gel transition temperature of the hydrogels was determined by differential scanning calorimetry (DSC) and viscometry. Discrepancies in the transition temperature among the various polymer systems were more pronounced when determined by viscosity compared by DSC, with the CPN showing a higher transition temperature than PNIPAAm. The cross-sectional structure and surface topography of the hydrogels were examined by scanning electronic microscopy (SEM) and atomic force microscopy (AFM), respectively. The incorporation of chitosan further increased the entanglement of the hydrogel network. An increase in the chitosan ratio in the polymers (CPN-H) also increased the cross-linking structure. A smoother surface of hydrogel matrices was observed for CPN compared with PNIPAAm. All hydrogels tested significantly reduced drug release compared with an aqueous solution. The release rate of platinum drugs from PNIPAAm was retarded at the late stage. CPN matrices could continuously deliver platinum drugs during the experiment. The rate of release from CPN-H was generally slower than that from hydrogels and had a lower chitosan ratio (CPN-L), presumably due to the more-tortuous pathways in the hydrogels. Thermosensitive hydrogels like those prepared in this study may be a promising carrier for the delivery of platinum drugs, as the drug release can be controlled and sustained using CPN networks.